How Sanofi’s CpG 1018 platform could reshape vaccine formulation in 2026
Sanofi's acquisition of CpG 1018 brings TLR9 adjuvants to the forefront. Explore how this could transform combo vaccines and adult immunization strategies.
Features & Analysis
Features & Analysis
Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
The recent FDA approval of Rubraca (rucaparib) for pre-chemotherapy use in BRCA-mutated metastatic castration-resistant prostate cancer marks a strategic inflection for the field. This expanded indication, driven by head-to-head superiority over docetaxel in the TRITON3 Phase 3 trial, positions BRCA mutations as the first molecular biomarker in prostate cancer to carry actionable, label-defining weight in
Features & Analysis
What is the regulome, and why is it becoming biotech’s new battleground?
Discover how biotech startups are targeting the regulome—the cell’s regulatory code—to unlock new drug targets beyond the genome and proteome.
Features & Analysis
Beyond biologics: Can structure-guided small molecules replace antibodies in intracellular targets?
For much of the past two decades, monoclonal antibodies have dominated modern drug development. Their ability to bind with high specificity, block protein function, and engage immune mechanisms has transformed the treatment of cancer, autoimmune disorders, and infectious disease. But despite their blockbuster status, biologics have a blind spot. They are largely excluded from the
Features & Analysis
Will AI-native drug discovery platforms create a new biotech category in 2026?
As 2026 begins, a new class of biotechnology companies is gaining prominence, not for any single drug, but for how they discover them. These firms, often referred to as AI-native biotechs, are reengineering the drug discovery process around machine learning. Unlike traditional pharmaceutical companies that apply algorithms to specific decision points in an existing workflow,
Features & Analysis
Beyond ovarian and breast cancer: Are PARP inhibitors finally proving their worth in urologic oncology?
The class of poly (ADP-ribose) polymerase inhibitors, once celebrated as a breakthrough in ovarian and breast cancer, has endured a reputation decline following safety concerns and regulatory rollbacks. But recent data suggest that prostate cancer, specifically metastatic castration-resistant prostate cancer with BRCA mutations, may offer PARP inhibitors a new lease on life. The December 2025
Features & Analysis
Can AI and chemistry finally converge to drug transcription factors? The race to target the cell’s command center
For decades, pharmaceutical pipelines have danced around one of biology’s most powerful but untouchable entities: transcription factors. These master regulators control gene expression and orchestrate cellular behavior, yet their structure and function have kept them out of reach for small molecule therapeutics. Unlike enzymes or receptors, transcription factors operate deep within the cell nucleus, often
Features & Analysis
Can oral GLP-1s maintain weight loss after injectables? Lilly’s orforglipron may prove it can
Eli Lilly and Company (Lilly) has reported positive topline results from the ATTAIN-MAINTAIN Phase 3 trial evaluating orforglipron, its once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for maintenance of weight loss in patients previously treated with injectable incretins. The trial enrolled participants who had completed 72 weeks of treatment with semaglutide (Wegovy) or tirzepatide (Zepbound)
Features & Analysis
Can Chinese biopharma finally break the innovation ceiling in autoimmune disease? Inside the IBI3011 playbook
For decades, China’s biopharma sector was best known for its rapid scaling of biosimilars, generics, and “fast follower” biologics. Industry watchers, both inside and outside the country, regarded Chinese firms as volume leaders but not science front-runners. This is now changing. The first-in-human dosing of IBI3011, Innovent Biologics’ anti-IL-1RAP monoclonal antibody, marks a turning point
Features & Analysis
Can negative pressure therapy disrupt renal support in heart failure? Inside JuxtaFlow’s new approach
Roivios Ltd., a clinical-stage medical device developer focused on kidney health, has reported promising results from its first-in-human trial of the JuxtaFlow Renal Assist Device. This investigational system applies controlled negative pressure to the renal pelvis to enhance urine output and sodium excretion in patients with diuretic-resistant cardiorenal syndrome and acute decompensated heart failure. While